649 related articles for article (PubMed ID: 10628899)
21. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
22. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum.
Canaparo R; Finnström N; Serpe L; Nordmark A; Muntoni E; Eandi M; Rane A; Zara GP
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1138-44. PubMed ID: 17880367
[TBL] [Abstract][Full Text] [Related]
23. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
24. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
25. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis.
Yang HY; Lee QP; Rettie AE; Juchau MR
Mol Pharmacol; 1994 Nov; 46(5):922-8. PubMed ID: 7969081
[TBL] [Abstract][Full Text] [Related]
26. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
28. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
Usmani KA; Hodgson E; Rose RL
Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
[TBL] [Abstract][Full Text] [Related]
29. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
30. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
31. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.
Saiz-Rodríguez M; Almenara S; Navares-Gómez M; Ochoa D; Román M; Zubiaur P; Koller D; Santos M; Mejía G; Borobia AM; Rodríguez-Antona C; Abad-Santos F
Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32331352
[TBL] [Abstract][Full Text] [Related]
32. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.
Kasahara M; Suzuki H; Komiya I
Drug Metab Dispos; 2000 Apr; 28(4):409-17. PubMed ID: 10725309
[TBL] [Abstract][Full Text] [Related]
33. Overlapping between CYP3A4 and CYP3A7 expression in the fetal human liver during development.
Fanni D; Fanos V; Ambu R; Lai F; Gerosa C; Pampaloni P; Van Eyken P; Senes G; Castagnola M; Faa G
J Matern Fetal Neonatal Med; 2015 Jul; 28(11):1291-1295. PubMed ID: 25208228
[TBL] [Abstract][Full Text] [Related]
34. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
35. Factors affecting cytochrome P-450 3A activity in cancer patients.
Baker SD; van Schaik RH; Rivory LP; Ten Tije AJ; Dinh K; Graveland WJ; Schenk PW; Charles KA; Clarke SJ; Carducci MA; McGuire WP; Dawkins F; Gelderblom H; Verweij J; Sparreboom A
Clin Cancer Res; 2004 Dec; 10(24):8341-50. PubMed ID: 15623611
[TBL] [Abstract][Full Text] [Related]
36. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
37. Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates.
Fujino C; Sanoh S; Katsura T
Biol Pharm Bull; 2021; 44(11):1617-1634. PubMed ID: 34719640
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450-mediated metabolism in the human gut wall.
Thelen K; Dressman JB
J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
[TBL] [Abstract][Full Text] [Related]
39. In vitro and pharmacophore insights into CYP3A enzymes.
Ekins S; Stresser DM; Williams JA
Trends Pharmacol Sci; 2003 Apr; 24(4):161-6. PubMed ID: 12707001
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells.
Kuang Z; Huang Z; Li Y; Yang G; Liu M; Yuan H
Mol Med Rep; 2015 Apr; 11(4):2868-74. PubMed ID: 25434721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]